Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later this year.
Related Keywords
Barbara Weber , Astrazeneca Plc , Tango Therapeutics Inc , Tango Therapeutics ,
comparemela.com © 2020. All Rights Reserved.